Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 19/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 5/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24316461 | 1.00 | CSF1R (0.49) | CSF1RPDGFRAFLT3KDRMET | |
| SCHEMBL29539467 | 1.00 | CSF1R (0.49) | CSF1RPDGFRAFLT3KDRMET | |
| SCHEMBL24316458 | 0.93 | CSF1R (0.49) | CSF1RPDGFRAFLT3KDRMET | |
| SCHEMBL29539378 | 0.93 | CSF1R (0.49) | CSF1RPDGFRAFLT3KDRMET | |
| SCHEMBL24316462 | 0.93 | CSF1R (0.49) | CSF1RPDGFRAFLT3KDRMET | |
| SCHEMBL29539281 | 0.92 | CSF1R (0.46) | CSF1RPDGFRAFLT3KDRMET | |
| SCHEMBL24317049 | 0.92 | CSF1R (0.46) | CSF1RPDGFRAFLT3KDRMET | |
| SCHEMBL24317050 | 0.92 | CSF1R (0.46) | CSF1RPDGFRAFLT3KDRMET | |
| SCHEMBL24317121 | 0.91 | CSF1R (0.49) | CSF1RPDGFRAFLT3KDRMET | |
| SCHEMBL24316633 | 0.91 | CSF1R (0.49) | CSF1RPDGFRAFLT3KDRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022057895-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-03-24 | — | — | WO | disclosed |
| US-9585884-B2 | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |